La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced that, following the negative results of the Riquent Phase 3 interim efficacy analysis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE